Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Malignant Neoplasm in the Lymph Nodes Clear all
Recruiting Early Phase 1 Interventional

RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis

NCT06216938
View directory record Official record
Conditions
Melanoma
Interventions
Vusolimogene oderparepvec (RP1)
Biological
Lead sponsor
Yana Najjar
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Terminated Phase 2 Interventional Results available

Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer

NCT02408887
View directory record Official record
Conditions
Low-risk Papillary Thyroid Cancer, Endocrine Malignancy, Thyroid Cancer
Interventions
Total Thyroidectomy (TT), Prophylactic central neck lymph node dissection (pCND)
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2022 · Synced Jul 23, 2026, 2:22 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer

NCT00753220
View directory record Official record
Conditions
Prostate Cancer
Interventions
VDC2008, Cyclophosphamide
Biological · Drug
Lead sponsor
Bostwick Laboratories
Industry
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Jul 23, 2026, 2:22 PM EDT
Active, not recruiting Phase 3 Interventional

Adjuvant Avelumab in Merkel Cell Cancer

NCT03271372
View directory record Official record
Conditions
Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIA Merkel Cell Carcinoma AJCC v8
Interventions
Avelumab, Peripheral Blood Collection, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
9
States / cities
Orange, California • Aurora, Colorado • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Recruiting Not applicable Interventional

Urologic Lymphadenectomy in AMIGO

NCT05132283
View directory record Official record
Conditions
Urologic Cancer, Lymph Node Metastasis
Interventions
3D Slicer, Monaco
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Not applicable Interventional

Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases

NCT03281720
View directory record Official record
Conditions
Breast Cancer
Interventions
TAD
Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Jul 23, 2026, 2:22 PM EDT
Recruiting No phase listed Observational

Distribution of Lymph Node Metastases in Esophageal Carcinoma

NCT03222895
View directory record Official record
Conditions
Esophageal Neoplasms, Lymph Node Metastases
Interventions
Not listed
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

NCT02364557
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Spine, Prognostic Stage IV Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Interventions
Stereotactic Body Radiotherapy, Surgery
Radiation · Procedure
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
153
States / cities
Birmingham, Alabama • Goodyear, Arizona • Peoria, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Recruiting Not applicable Interventional

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

NCT06389786
View directory record Official record
Conditions
Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 85 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Early Phase 1 Interventional

Ultrasound-Guided Photoacoustic Imaging for the Detection of Metastases in Inguinal Lymph Nodes

NCT04185337
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Fine-Needle Aspiration, Lymph Node Biopsy, Photoacoustic Imaging, Ultrasound, Multispectral optoacoustic tomography (MSOT) acuity instrument
Procedure · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Jul 23, 2026, 2:22 PM EDT
Active, not recruiting Phase 3 Interventional

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

NCT03793166
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Malignant Neoplasm in the Soft Tissue, Metastatic Malignant Neoplasm in the Viscera, Rhabdoid Tumor of the Kidney, Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
859
States / cities
Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 555 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed No phase listed Observational

Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)

NCT06381648
View directory record Official record
Conditions
Cholangiocarcinoma, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma Resectable, Cholangiocarcinoma; Liver
Interventions
LyMIC (Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma)
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Suspended Phase 1Phase 2 Interventional

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

NCT04071236
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Stage IVB Prostate Cancer AJCC v8
Interventions
Avelumab, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Peposertib, Questionnaire Administration, Radium Ra 223 Dichloride
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
32
States / cities
Duarte, California • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 3 Interventional

Radiation Therapy in Treating Patients With Metastases to the Lymph Nodes in the Neck From an Unknown Primary Tumor

NCT00047125
View directory record Official record
Conditions
Carcinoma of Unknown Primary
Interventions
radiation therapy
Radiation
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
18 Years to 120 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
237
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2018 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 2 Interventional

Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized Trial

NCT00001250
View directory record Official record
Conditions
Breast Neoplasm, Neoplasm Metastasis
Interventions
preoperative dose intense chemotherapy (FLAC/G-CSF)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1989 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 2:22 PM EDT
Not listed Phase 1 Interventional

Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer

NCT01295502
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB Cervical Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7
Interventions
Carboplatin, Cisplatin, External Beam Radiation Therapy, Internal Radiation Therapy, Paclitaxel
Drug · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
14
States / cities
Orange, California • Hartford, Connecticut • New Britain, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer

NCT03796767
View directory record Official record
Conditions
Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Oligometastasis, Prostate Adenocarcinoma, PSA Failure
Interventions
Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Metastasectomy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Procedure · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

NCT00416455
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma, Stage I Endometrial Carcinoma, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage IVA Cervical Cancer
Interventions
fludeoxyglucose F 18, positron emission tomography, computed tomography, ferumoxtran-10, magnetic resonance imaging, diagnostic lymphadenectomy, lymph node biopsy
Radiation · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
24
States / cities
Los Angeles, California • Sylmar, California • New Britain, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 2 Interventional

Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus

NCT00066716
View directory record Official record
Conditions
Esophageal Cancer
Interventions
carboplatin, celecoxib, paclitaxel, adjuvant therapy, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2009 · Synced Jul 23, 2026, 2:22 PM EDT
Terminated Not applicable Interventional

Axillary Lymph Node Tattoo Marking Study

NCT04947917
View directory record Official record
Conditions
Breast Cancer, Lymph Node Metastases
Interventions
SpotTM Tattoo Ink
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer

NCT01076335
View directory record Official record
Conditions
Prostate Cancer
Interventions
Neoadjuvant Hormonal Therapy, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Not applicable Interventional

Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer

NCT00080860
View directory record Official record
Conditions
Breast Cancer
Interventions
microarray analysis, immunohistochemistry staining method, conventional surgery, lymphangiography, radionuclide imaging, sentinel lymph node biopsy, technetium Tc 99m sulfur colloid
Genetic · Other · Procedure + 1 more
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Jul 23, 2026, 2:22 PM EDT
Recruiting Not applicable Interventional

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

NCT03796559
View directory record Official record
Conditions
Breast Cancer, Axillary Lymph Nodes
Interventions
Magseed Marker
Device
Lead sponsor
Endomagnetics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 2:22 PM EDT
Completed Not applicable Interventional

Selective Image Guided Resection of Axillary Lymph Nodes

NCT01880645
View directory record Official record
Conditions
Breast Cancer
Interventions
Fine Needle Aspiration (FNA), Ultrasound, Breast Surgery + Lymph Node Removal
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Jul 23, 2026, 2:22 PM EDT